Concepedia

Qingxia Fan

QF

Statistics

Publications

80

Citations

4.8K

H-Index

34

Active since

2009

Affiliations

First Affiliated Hospital of Zhengzhou University(Current)

Henan Cancer Hospital

Zhengzhou University

Chinese Academy of Medical Sciences & Peking Union Medical College

Peking University Cancer Hospital

Qingxia Fan is an author at First Affiliated Hospital of Zhengzhou University specializing in oncology, medicine, and molecular oncology.

ORCID

Publications per year

2009–2024

80

Publications

80

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Jin Lü, Yuxian Bai, Teng Mao et al. · JAMA · 2021 · 801 citations · Full text

, , +17

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang, Jianming Xu, Yun Chen et al. · The Lancet Oncology · 2020 · 584 citations

, , +14

Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

Zhi Peng, Tianshu Liu, Jia Wei et al. · Cancer Communications · 2021 · 202 citations · Full text

, , +16

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

Jianming Xu, Yi Li, Qingxia Fan et al. · Nature Communications · 2022 · 150 citations · Full text

, , +17

Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

Yingying Xu, Yakun Wang, Jifang Gong et al. · Gastric Cancer · 2021 · 149 citations · Full text

, , +17

1–5 of 80